NEW 1-BENZYL-3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

Abstract: The invention relates to the new 6,7-diethoxy-1-(4-­ ethoxy-3-hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula I and physiologically acceptable salts thereof. The compound of the Formula I and salts thereof can be prepared by hydrolysing a compound of the general Formula VI (wherein R¹ is a group removable by hydrogenolysis) preferably a benzyl group and R is an alkyl group having 1-6 carbon atoms), reacting the compound of the general Formula V thus obtained (wherein R¹ is as stated above) with an amine of the general Formula IV or a salt thereof in the presence of a catalyst, subjecting the amide of the general Formula III thus obtained (wherein R¹ is as stated above) to ring-closure and subjecting the compound of the General Formula II (wherein R¹ is as stated above) or a salt thereof thus obtained to hydrogenolysis and if desired converting the compound of the Formula I thus obtained into a physiologically acceptable salt thereof or setting free the same from its salt.

Description: This invention relates to a new l-benzyl-3,Afr dihydro-isoquinoline derivative, a process for the preparation thereof and pharmaceuticel compositions containing the same. According to a feature of the present invention there is provided the new 6,7-diethoxy-l-(4-ethoxy-3hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula I EMI1.1 and physiologically acceptable salts thereof. The nevç compound of the Formula I and salts thereof possess useful physiological properties and exhibit particularly useful effects on the circulation. The physiologically acceptable salts of the Formula I may be formed with inorganic or organic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid a oxalic acid a tartaric acid, succinic acid, citric acid a maleic acid a salicylic acid, benzoic acid etc. The salts may be neutral (e.g. sulfates or phosphates) or acidic (e.g. hydrogen sulfates, hydrogen phosphates) salts. According to a further feature of the present invention there is provided a process for the preparation of the compound of the Formula I and physiologically acceptable salts thereof which comprises hydrolysing a compound of the general Formula VI EMI2.1 (wherein R1 is a group removable by hydrogenolysis, preferably a benzyl group and R is an alkyl group having 1-6 carbon atoms) reacting the compound of the general Formula V EMI2.2 thus obtained (wherein 1ll is as stated above) with an amine of the Formula IV EMI2.3 or a salt thereof in the presence of a catalyst, subjecting the amide of the general Formula III EMI3.1 thus obtained (wherein R1 is as stated above) to ringclosure and subjecting the compound of the general Formula II EMI3.2 (wherein R1 is as stated above) or a salt thereof thus obtained to hydrogenolysis and if desired converting the compound of the Formula I thus obtained into a physiologically acceptable salt thereof or setting free the same from its salt, The term "alkyl group having 1-6 carbon atoms" relates to straight or branched chained saturated aliphatic hydrocarbon groups having 1-6 carbon atoms (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl etc.). R1 may stand for any suitable group which can be removed by hydrogenolysis and preferably means benzyl. In the first step of the process of the present invention a compound of the general Formula VI is hydrolysed preferably with an alkali metal hydroxide. On acidifying the reaction mixture with a mineral acid a compound of the general Formula V is obtained and the precipitated solid product can be isolated preferably by filtration. The reaction of the compounds of the general Formulae IV and V is preferably carried out in a solvent (e.g. benzene, toluene or xylene) in the presence of a catalyst capable of delivering protons, As catalyst capable of delivering protons mineral acids sulfonic acids or cation-exchanging resins can be used. The reaction can be carried out preferably at the boiling point of the mixture and the water formed in the reaction is removed by azeotropic distillation. The reaction having been completed the reaction mixture is cooled and the precipitated acid amide of the general Formula III is isolated by filtration. The cyclisation of the compounds of the general Formula III can be carried out in the presence of a condensing agent (preferably phosphoryl chloride, phosphorous pentachloride, thionyl chloride or polyphosphoric acid or a mixture thereof) in the presence or absence of an organic solvent, As solvent e.g. aromatic hydrocarbons or acetonitrile can be used. Cyclisation can be carried out in a broad temperature range. The compounds of the general Formula II thus obtained are subjected to hydrogenolysis. The reaction can be preferably accomplished by means of catalytic hydrogenation and can be advantageously effected in the presence of an acid. The catalytic hydrogenation of the compounds of the general Formula II can be carried out in a solvent (e.g. lower aliphatic alcohols) in the presence of a heterogenous catalyst (e.g. Raney-nickel, platin or palladium charcoal). Hydrogenation can be carried out under atmospheric or higher pressure. The compound of the Formula I can be isolated from the reaction mixture by known methods. The compound of the Formula I can be purified by crystallization from suitable lower aliphatic alcohols but a methanol-ether mixture or ethyl acetate can also be used as crystallizing solvent. The compound of the Formula I can be converted into its salts formed with physiologically acceptable inorganic or organic acids (e.g. aromatic or aliphatic mono- or dicarboxylic acids, hydroxy acids alkyl sulfonic acids, aryl sulfonic acids1 amino acids, mineral acids etc.) by methods known per se. The compound of the Formula I can also be set free from its salts by known methods. The preparation of the starting material of the Formula VI is known from prior art E. Het. Chew. 7 339-343 (1970)1. The 6,7-diethoxy-1-(3-etlloxy-4-hydroxy-benzyl)-3,4- dihydro-isoquinoline being structurally similar to the compound of the Formula I can also be prepared by the process of the present invention and is known from prior art. [European journal of Drug Metabolism and Pharmacokinetics 5 (2) 69-74 (1980)1. The compound of the Formula I exhibits useful physiological and particularly cardiovascular effects. The anti-angina activity is determined by measuring the inhibition of the acute coronary insufficiency (which corresponds to the rise of the T-wave on the electrocardiogram) induced by vasopressine (2 IU/kg i.v.) on pentobarbital anaesthetized (45 mg/kg i.p,) rats belonging to the CFY strain (method of Papp and Szekeres: Arch. Int. Pharmacodyn. 160, 147 /1966/). The antiarrhythmial effect is determined on chloralose-urethane anaesthetized cats (500/300 mg/kg i.p.l by measuring the changes of the electric fibrillation threshold of the auricle and ventricle respectively method of Szekeres, Meshes and Papp: Brit. a. Pharmacol. 17, 167 (1961) and that of Szekeres and Papp: Hdb. exp. Pharmacol. 16/3, 131 (1975) respectively]. The general effects exerted on the haemodynamic and cardiovascular system are tested on pentobarbital anaesthetized dogs (35 mg/kg i.v0)0 The compound of the Formula I exhibits significant anti-angina effect (the activity related to that of papaverin amounts to 1.40), it shows an expressed auricle and ventricle antiarrhythmial and antifibrillatory effect respectively (Table I) and acts advantageously on several parameters of the function of the cardiovascular system too (Table 1). Thus among others the compound of the present invention increases the blood-flow of peripherial bloodvessels (arteria femoralis, carotis, vertebralis)l decreases the resistence of the said blood-vessels and improves the efficiency of cardial function. Due to the antiangina activity it increases coronary flow, decreases coronary resistance and the oxygen consumption of the left ventricle, increases the myocardial oxygen supply per oxygen consumption quotient and thus improves the oxygenization of the cardial muscle to a significant extent. The compound of the Formula I is a potent drug in the treatment of cardiovascular dieeases, particularly Angina pectoris, auricle,and ventricle arrhythmia and peripherial circulatory disorders causEd by reduced blood flow. The structurally similar 6,7-diethoxy-1-(3-ethoxy-4- hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula VII EMI7.1 is described in prior art as a metabolit of Drotaverin. This compound also exhibits an anti-angina effect (its activity related to that of papaverin amounts to 1.28) and accordingly increases coronary flow, decreases coronary resistance and the oxygen consumption of the left ventricle, it increases the myocardial oxygen supply per oxygen consumption quotient and thereby improves the oxigenization of the cardial muscle (Table 2), The compound of the Formula VII rises the fibrillation threshold of the auricle and ventricle too and also exhibits anti-arrhythmial activity (Table 2). Contrary to the compound of the Formula I of the present invention, the compound of the Formula VII decreases the blood flow of peripherial blood-vessels (Arteria femoralis carotids vertebralis) and at the same time increases the resistance of the said blood-vessels, thus it can not to be used for the treatment of peripherial circulatory disorders or for the improvement of the blood supply of the limbs or of the brain. The acute toxicity of the compound of the Formula I is characterized by the data enumerated in Table 3. Table 1 Summary of the tested main circulatory-pharmacological effects of the 6,7-diethoxy 1-(4-ethoxy-3-hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula I on anaesthetized dogs and cats (average 4 S.E.) (Dose: 2 mg/kg i.v.) Percental Duration of Parameter n Basic value Changed value difference effect (min) Arterial blood pressure (Hgmm) (on dogs) 12 121 # 5 94 # 4 -22 5 Heart frequence/min (on dogs) 10 146 # 8 114 # 9 -22 31 Contractibility of the left ventricle (dP/dt, Hgmm/sec, on dogs) 6 5105 # 434 5248 # 865 -17 2 Minute volume (ml/min) (on dogs) 6 875 # 42 975 # 34 +11 4 Frequence volume /ml/ (on dogs) 6 5.5 # 0.3 8.8 # 0.9 +60 35 Total peripherial resistance (dyn. sec. cm-1, on dogs) 6 10552 # 991 8185 # 748 -23 5 Function of the left ventricle (mkg/min, on dogs) 6 1.24 # 0.08 0.99 # 0.16 -20 7 Coronary flow (ml/min/100 g, on dogs) 6 95 # 5 129 # 9 +36 16 Coronary resistance (Hgmm/ml/min/100 g, on dogs) 7 1.16 # 0.06 0.76 # 0.08 -34 15 Table 1 continued Percental Duration of Parameter n Basic value Changed value difference effect (min) Oxygen consumption of the left ventricle (ml/min/100 g, on dogs) 6 11.6 # 0.9 8.2 # 1.2 -29 22 Efficiency of cardial function (mkg/ml/100 g, on dogs) 6 0.11 # 0.02 0.16 # 0.02 +45 6 Myocardial oxygenization (O2 supply per O2 consumption, on dogs) 6 1.70 # 0.07 2.95 # 0.21 +74 30 A. femoralis flow (ml/min) 6 34 # 7 49 # 10 +44 3 A. femoralis resistance (Hgmm/ml/min, on dogs) 6 4.84 # 0,86 2.66 # 0.42 -45 3 A. carotis flow (ml/min, on dogs) 6 70 # 7 89 # 13 +27 7 A. carotis resistance (Hgmm/ml/min, on dogs) 6 2.33 # 0.23 2.02 # 0.32 -13 7 A. vertebralis flow (Hgmm/ml/min, on dogs) 6 43 # 6 65 # 9 +51 2 A. vertebralis resistance (Hgmm/ml/min, on dogs) 6 3.28 # 0.33 1.81 # 0.17 -45 2 Table 1 continued Percental Duration of Parameter n Basic value Changed value difference effect (min) Auricle fibrillation threshold (mA, in cats) 6 0.73 # 0.10 1.15 # 0.11 +58 11 Ventricle fibrilation threshold (mA, on cats) 6 2.07 # 0.10 2.58 # 0.09- +25 13 Arterial blood pressure (Hgmm, on cats) 6 139 # 5 79 # 8 -43 9 Table 2 Summary of the tested main circulatory-pharmacological effects of the 6,7 diethoxy-1-(ethoxy-4-hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula VII on anaesthetized dogs and cats (average + S.E.) (Dose: 1 mg/kg i.v.) Percental Duration of Parameter n Basic value Changed value difference effect (min) Arterial blood pressure (Hgmm) (on dogs) 6 147 # 9 115 # 11 -22 8 Heart frequence/min (on dogs) 6 173 # 8 169 # 9 - 8 7 Contractibility of the left ventricle (dP/dt, Hgmm/sec, 6 5525 # 557 4883 # 419 -13 -13 on dogs) Minute volume (ml/min) (on dogs) 5 1500 # 153 1466 # 233 - 2 3 Frequence volume (ml) (on dogs) 5 8.8 # 1 9.5 # 1.2 + 8 5 Total peripherial resistance (dyn. sec. cm-5, on dogs) 5 7015 # 238 4786 # 275 -32 14 Function of the left ventricle (mkg/min, on dogs) 5 2.74 # 0.49 2.22 # 0.56 -19 13 Coronary flow (ml/min/100 g, 5 73 # 13 86 # 13 +18 15 on dogs) Coronary resistance (Hgmm/ml/min/100 g, on dogs) 5 1.03 # 0.10 1.42 # 0.22 -22 11 Table 2 continued Percental Duration of Parameter n Basic value Changed value difference effect (min) Oxygen consumption of the left ventricle (ml/min/100 g, on dogs) 5 8.4 # 0.9 7.9 # 1.9 - 6 9 Efficiency of cardial function (mkg/ml/100 g on dogs) 5 0.32 # 0.03 0.28 # 0.05 +13 20 Myocardial oxygenization (O2 supply per O2 consumption, on dogs) 5 1.62 # 0.06 1.79 # 0.10 +10 18 A. femoralis flow (ml/min) 5 46 # 5 42 # 5 - 9 11 A. femoralis resistance (Hgmm/ml/min, on dogs) 5 3.48 # 0.45 3.69 # 0.68 - 6 18 A. carotis flow (ml/min, on dogs) 5 91 # 9 80 # 10 -12 12 A. carotis resistance (Hgmm/ml/min, on dogs) 5 2.04 # 0.3 2.19 # 0.4 + 7 15 A. vertebralis flow (Hgmm/ml/min, on dogs) 5 54 # 9 50 # 7 - 7 7 Table 2 continued Percental Duration of Parameter n Basic value Changed value difference effect (min) A. vertebralis resistance (Hgmm/ml/min, on dogs) 5 3.22 # 0.61 3.65 # 0.32 +12 12 Auricle fibrillation threshold (mA, on cats) 5 0.52 # 0.07 0.77 # 0.19 +48 9 Ventricle fibrillation threshold (mA, on cats) 5 0.70 # 0.10 1.00 # 0.18 +43 12 Arterial blood pressure (Hgmm, on cats) 5 142 # 11 110 # 16 -23 5 Table 3 Acute toxicity data of the 6a7-diethoxy-l-(4-ethoxy 3-hydroxy-benzyl)-3,4-dihydro-isoquinoline of the Formula I LD50 = 24.92 mg/kg i.v. on rats Ï = 22.98 mg/kg i.v. on rats or LD50 = 269,18 mg/kg p.o, on mice o" = 164,99 mg/kg p.o. on mice o LD50 = 493 mg/log p.o. on rats oA = 625 mg/kg p.o. on rats According to a further feature of the present invention there are provided pharmaceutical compositions comprising as active ingredient the compound of the Formula I or a physiologically acceptable salt thereof in admixture with suitable inert non-toxical solid or liquid carriers or diluents. The pharmaceutical compositions may be used either in solid (e.g. tablet , capsule, dragée) or liquid (e.g. solution, suspension, emulsion) form. The active ingredient content of the pharmaceutical compositions may vary between wide ranges and may be from about 0.001 to about 95 %. The daily active ingredient dosage may also vary between wide ranges and depends on the various circumstances of the given case (e.g. seriousness of the state of the patient, age and body weight of the patient, the formulation used, the activity of the active ingredient etc.). The pharmaceutical compositions of the present invention can be prepared by methods of pharmaceutical industry known per se. Further details of the present invention are to found in the Examples without limiting our invention to the said Examples. Example 1 20.0 g (66.6 mmoles) of methyl-(3-benzyloxy-4- ethoxy-phenyl)-acetate and 100 ml of a 10 ', by weight sodium hydroxide solution are stirred at 110 OC for 2 hours. After solid substance has been completely dissolved the solution is cooled in an ice-water bath to +10 OC and acidified with concentrated hydrochloric acid to the pH value of 1. The precipitated flocky white crystals are filtered off a washed with distilled water and dried in a vacuo desiccator. The crude product is recrystallized from a mixture of benzene and petrolether. Thus 17.9 g of 3-benzyloxy-4-ethoxy-phenyl-acetic acid are obtained, yield. 93.8 %. Mp.: 95-97 OC Analysis: for the Formula C17H18O4 calculated: C 71.31 D H 6.33 %; found: C 71.18 % H 6.11%. IR (in a potassium bromide capsule): 1712 cm 1 EMI16.1 NMR: (solvent CDCl3): 1.38 (t, 3H, CH3-; 3.44 (s, 2H, -CH2-COO-; 3.77-4.26 (q, 2H, -CH2-; 5.03/s, 2H, benzyl-CH2; 6.47-7.57/m 8H, aromatic H; 9.85/s, 1H, -COOH. Example 2 6.30 g (22.0 mmoles) of 3-benzyloxy-4-ethoxy-phenylacetic acid are dissolved in 60 ml of xylene. 4.80 g (22.9 mmoles) of 3,4-diethoxy-ss-phenyl-ethyl amine and 1 g of Varion KS cation exchanging resin (previously washed with 5 N hydrochloric acid and distilled water) are added. The reaction mixture is heated to boiling under a water-separator until an equivalent amount of water is removed. The hot solution is filtered, the filtrate is cooled and allowed to crystallize. The precipitated crystalline substance is filtered off, washed with petrolether and dried. Thus 8.20 g of N-(3-benzyloxy 4-ethoxy-phenyl-acetyl)-3,4-diethoxy-ss-phenyl-ethyl-amide are obtained, yield: 78.0 , , mp.: 123-124 C. Analysis for the Formula C29H55NO5; calculated: C 72.92 % H 7.38 % N 2.93 %; found: C 72.86 % H 7.59 S N 2.89 %. IR (in a potassium bromide pastille): 1641 1 ( C=O) NMR (solvent CDCl3): 1.39 and 1.44 (t, 9H, OH3-); 2.59 (t, 2H1 Ar-CH2-CH2-), 3.08-3.68 (m, 4H, -CH2-C=O); -CH2-N=C-0)i 3.78-4.37 (m, 6H, CH3-CH2-O-); 5.04 (a, 2H, benzyl-CH2-);, 5.40 (s, 1H, -NH-); 6.28-7.58 (m, 11H, aromatic H). Example 3 10.0 g (20.9 mmoles) of N-(3-benzyloxy-4-ethoxyphenyl-acetyl)-3,4-diethoxy-ss-phenyl-ethyl-amide are dissolved in 60 ml of anhydrous chloroform. The solution is cooled to O C, whereupon a suspension of 5.60 g (26.8 mmoles) of phosphorous pentachloride and 60 ml of anhydrous chloroform is added at 0 C. The mixture thus obtained is allowed to stand at 0 C for 30 minutes and at room temperature for 2 days. The reaction mixture is diluted with anhydrous ether. The precipitated crystalline substance is filtered off washed with anhydrous ether and dried0 Thus 9.65 g of 1-(3-benzyloxy-4-ethoxy-benzyl)- 6,7-diethoxy-3,4-dihydro-isoquinoline-dihydrochloride are obtained, yield: 92.9 cÓ, mp.; 209-210 OC (decomposition). Analysis: for the Formula C29H34ClNO4; calculated: d 70.21 cÓ H 6.90 % N 2.82 %, found: C 69.80 cÓ H 6.70 S N 3.25 %, IR (in a potassium bromide pastille): 1670 cm-1 ( > Example 4 3.50 g (7.05 mmoles) of 1-(3-benzyloxy-4-ethoxy-benzyl)- 6,7-diethoxy-3,4-dihydro-isoquinoline-hydrochloride are dissolved in 100 ml of methanol and the solution is poured into a pre-hydrogenated suspension of 1.50 g of a 10 % palladium/charcoal catalyst and 20 ml of methanol. The hydrogenation is carried out at atmospheric pressure and room temperature. The calculated amount of hydrogen (169 ml) is taken up within about 10 minutes. Hydrogenation is then stopped, the catalyst is filtered off, and the solvent is distilled off in vacuo. The residual solid crude product (2.80 g) is crystallized from a mixture of methanol and ether. Thus 2.00 g of 6.7-disthoxy-1- (4-ethoxy-3-hydroxy-benzyl)-6,7-dihydro-isoquinoline¯ hydrochloride are obtained, yield: 69.8 %, mp.: 223-225 C. Analysis for the Formula C22H28C1NO4: calculated: C 65.09 csÓ H 6.95 % N 3.45 %; found: C 64.97 D H 6.99 % N 3.66 . IR (potassium bromide capsule): 3300 cm-1 (-OH); 1622 cm-1 (#C=N-). Example 5 30 mg tablets are prepared (batch-size 10.000 -tablets). The following components are used: Component Amount, q a) Compound of the Formula I 300 b) Potato starch 530 c) Lactose 600 d) Gelatine 18 e) Distilled water 100 f) Ethanol (96 vol.%) 200 g) Sodium pyrosulfite 2 h) Talc 30 i) Stearic acid 20 The homogenous powder mixture of components a), b) and c) is wetted with a solution of components d), e), f) and g) in a suitable kneading machine in small portions, whereupon ti is granuled on a sieve (mash size 0.3 mm) and dried at 40 C. The dry granules are re-granulated on a sieve (mash size 0.15 mm), thoroughly admixed with the homogenous powder mixture of components h) and i) and pressed into tablets weighing 150 mg. Example 6 100 mg retard tablets and drags are prepared (batch size 10.000). The following components are used: Component Amount, g a) Compound of the Formula 1 1000 b) Crystalline cellulose 450 c) Lactose 765 d) Copolymer of vinyl pyrrolidone and vinyl acetate 180 e) Distilled water 150 f) Ethanol (96 vol. ) 350 g) Sodium pyrosulfite 5 h) Colloidal silicic acid 24 i) Magnesium stearate 25 j) Stearine 50 The homogeneous powder mixture of components a), b) and c) is granulated and dried with a suspension of components d), e), f), g) and j) in an apparatus under overpressure at 40 0C according to the principle of fluidisation. The dry granules are regranulated on a sieve (mash size 0.15 mm), admixed with a homogeneous powder mixture of components h) and i) and pressed into tablets and capsules weighing 250 mg respectively, The active ingredient delivery of the tablets should reach 80 % within 6-11 hours according to the so-called "half-change" method. The drage core is coated with a sugar layer by methods known per se. Example 7 Injections containing 20 mg/2 cm3 are prepared (batch size 10.000). The following components are used: Component Amount a) Compound of the Formula 1 100 g b) Distilled water ad 10.000 ml c) Sodium pyrosulfite 15 g d) Sodium chloride 27 g The solution of components b), c) and d) is prepared under carbon dioxide and the exclusion of air, whereupon component a) is dissolved and the pH of the solution is adjusted to 3;7-4.2 with the aid of 1N hydrochloric or 1 N sodium hydroxide, if necessary. The solution is diluted to 10,000 ml and thereafter aseptically filtered sterile through a bacterium filter and filled into 2.2 ml ampoules in a known manner. The solution is filled into brown glass ampoules.

Claims: Claims: 1. 6,7-Diethoxy-1-(4-ethoxy-3-hydroxy-benzyl)-3,4 dihydro-isoquinoline of the Formula I EMI22.1 and salts thereof. 2. Process for the preparation of 6,7-diethoxy-l (4-e thoxy-3-hyd roxy-benzyl)-3,4-dihyd ro-isoquinoline of the Formula I EMI22.2 and physiologically acceptable salts thereof which comprises hydrolysing a compound of the general Formula VI EMI23.1 (wherein R1 is a group removable by hydrogenolysis, preferably a benzyl group and R is an alkyl group having 1-6 carbon atoms), reacting the compound of the general Formula V EMI23.2 thus obtained (wherein R1 is as stated above) with an amine of the Formula IV EMI23.3 or a salt thereof in the presence of a catalyst, subjecting the amide of the general Formula III EMI23.4 thus obtained (wherein R1 is as stated above) to ringclosure and subjecting the compound of the general Formula II EMI24.1 (wherein Rl is as stated above) or a salt thereof thus obtained to hydrogenolysis and if desired converting the compound of the Formula I thus obtained into a physiologically acceptable salt thereof or setting free the same from its salt. 3. Process according to Claim 2 which comprises hydrolysing a compound of the general Formula VI (wherein R and ,R1 are as stated in Claim 1) in alkaline medium. 4. Process according to Claim 2 which comprises using a catalyst capable of delivering protons, preferably a mineral acid, sulfonic acid or cation-exchanging resin. 5. Process according to Claim 2 which comprises carrying out the reaction of the compounds of the general R 1 Formulae V and IV (wherein R1 is as stated in Claim 2) in an organic solvent, preferably in an aprotic solvent as medium at the boiling point of the solvent. 6. Process according to Claim 2 which comprises carrying out ring-closure in the absence or presence of a solvent, preferably in chloroform, benzene or aceto nitrile, in the presence of phosphorous pentachloride,* phosphoryl chloride thionyl chloride or poly phosphoric acid or a mixture thereof. 7. Process according to Claim 2 which comprises isolating the compound of the general Formula II (wherein R1 is as stated in Claim 2) by making the reaction mixture alkaline and extracting with a solvent. 8. Process according to Claim 2 which comprises hydrogenating a compound of the general Formula II (wherein R1 is as stated in Claim 2) in the presence of a palladium/charcoal, platinum or Raney-nickel catalyst, preferably in an aliphatic alcohol having 1-4 carbon atoms, at atmospheric pressure and room temperature. 9. Process according to Claim 2 which comprises converting the compound of the Formula I into a neutral or acidic salt comprising a physiologically acceptable anion, preferably into the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, succinate, citrate, maleate, salicylate or benzoate. 10. Pharmaceutical composition comprising as active ingredient the compound of the Formula I or a physiologically acceptable salt thereof and an inert non-toxic carrier. 11. Process for the preparation of pharmaceutical compositions according to Claim 10 which comprises admixing the compound of the Formula I or a physiologically acceptable salt thereof with inert non-toxic carriers.

Inventors: DAVID, AGOSTON, GYORI, PETER, KALAUS, GYORGY, PAPP, GYULA, SZANTAY, CSABA, SZEKERES, LASZLO, UDVARY, EVA
Applicants: CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.
Application year: 1982
Main classification: C07D217
IPC codes: C07D217, A61K31, C07C59, A61P9